MedPath

A Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Nepafenac Ophthalmic Suspension 0.3% w/v compared to Bromfenac Ophthalmic Solution 0.09% w/v in the treatment of Pain and Inflammation post Cataract Surgery.

Phase 3
Completed
Conditions
Disorders of the eye following cataract surgery, Pain and Inflammation in the Eye associated with Cataract Surgery,
Registration Number
CTRI/2017/04/008299
Lead Sponsor
Ajanta Pharma Ltd
Brief Summary

This study is A Multicentric, Double Blind, Randomized,Active Control, Parallel Group Comparative Study to Evaluate the Efficacy,Safety and Tolerability of Nepafenac Ophthalmic Suspension 0.3 % w/v Vs.Bromfenac Ophthalmic Solution 0.09% w/v in the treatment of Patients with Painand Inflammation in the Eye associated with Cataract Surgery.

Primary objective of this study is to assess Ocularinflammation. Secondary objective of the study is to assess the Ocular pain andnumber of patients pain free at each visit post cataract surgery.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
278
Inclusion Criteria
  • 1.Male and Female patients of age 18.
  • 70 years (Both inclusive). 2.Planned cataract extraction by phacoemulsification with the implantation of a posterior chamber intraocular lens. 3.Voluntary willingness to give written informed consent prior to participation in trial.
Exclusion Criteria
  • 1.Use of topical ocular, inhaled or systemic nonsteroidal anti-inflammatory drugs within 7 days of surgery, with the exception of the allowed low dose of aspirin (up to 100 mg) prior to surgery and through study exit.
  • 2.Use of any form of steroids -topical, inhaled or systemic steroids within 14 days prior to surgery or local or oral NSAIDs within 7 days of surgery.
  • 3.History of chronic or recurrent inflammatory eye disease (eg, iritis, scleritis, uveitis, iridocyclitis, rubeosis iridis) in the operative eye.
  • 4.Pregnant and lactating women.
  • 5.Known or suspected allergy or hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), or to any component of the test article.
  • 6.Subjects with bleeding tendency, dry eye, rheumatoid arthritis, ocular surface disease including epithelial problems.
  • 7.Subject with any surgery which converted from phacoemulsification to extra capsular surgery.
  • 8.Patients with history of ocular surgery, inflammatory eye disease, ocular infection, congenital ocular anomalies, ocular trauma or current signs and symptoms that were associated with these or other ocular conditions.
  • 9.Lens pseudoexfoliation syndrome with glaucoma or zonular compromise or previous ocular trauma.
  • 10.Patients were also excluded if their IOP could not be reliably measured or had planned multiple surgical procedures, lens pseudoexfoliation syndrome with glaucoma or zonular compromise in the operative eye, ocular or systemic inflammatory or diabetic disease, or previous ocular trauma to the operative eye.
  • 11.Patient with Diabetic Retinopathy, Glaucoma and any other Neurological condition.
  • 12.Any other condition(s) that may affect the procedure of the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Ocular inflammation as assessed by the investigator during slit lamp examinationDay 1,Day 7,Day 14
Secondary Outcome Measures
NameTimeMethod
Ocular pain will be assessed using a categorical scale.Percentage of patients Pain Free at each visit post cataract surgery.

Trial Locations

Locations (18)

Bhagwan mahaveer Jain Hospital

🇮🇳

Bangalore, KARNATAKA, India

BJ Medical College & Civil Hospital

🇮🇳

Ahmadabad, GUJARAT, India

BYL Nair Ch. Hospital and TN Medical College

🇮🇳

Mumbai, MAHARASHTRA, India

Christian Medical College and Hospital

🇮🇳

Ludhiana, PUNJAB, India

Dr. R.S.P.R. Government Regional Eye Hospital

🇮🇳

Visakhapatnam, ANDHRA PRADESH, India

Gandhi Hospital

🇮🇳

Hyderabad, ANDHRA PRADESH, India

GMERS Medical College and Civil Hospital

🇮🇳

Ahmadabad, GUJARAT, India

IPGME&R, SSKM Hospital

🇮🇳

Kolkata, WEST BENGAL, India

Kakatiya Medical College

🇮🇳

Warangal, ANDHRA PRADESH, India

Kanoria Hospital & Research Center

🇮🇳

Gandhinagar, GUJARAT, India

Scroll for more (8 remaining)
Bhagwan mahaveer Jain Hospital
🇮🇳Bangalore, KARNATAKA, India
Dr Rajesh Parekh
Principal investigator
9945544744
eyetrials@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.